Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858645 · ClinicalTrials.gov registry record · Phase 4
Correction of Psoriatic T Cell Signatures by Deucravacitinib
A Phase 4 study of Psoriasis Vulgaris, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05858645 is a Phase 4 study of Psoriasis Vulgaris that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 88-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05858645, a Phase 4 study of Psoriasis Vulgaris, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Conditions Studied
Interventions
- DRUG deucravacitinib
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05858645
The ClinicalTrials.gov registry entry for NCT05858645 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (72% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which deucravacitinib is the first listed.
NCT05858645 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05858645 about?
NCT05858645 is a clinical study titled "Correction of Psoriatic T Cell Signatures by Deucravacitinib". This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
What is the current status of trial NCT05858645?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2023-10-01. Estimated completion is 2026-06.
What conditions does trial NCT05858645 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris.
What interventions are being tested in trial NCT05858645?
The interventions under investigation include: deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT05858645?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05858645 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Use of Botulinum Toxin to Treat Psoriasis
COMPLETED · Phase 1
-
Blue Light Phototherapy
COMPLETED · NA
-
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
COMPLETED · Phase 2
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
-
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.